These findings imply a strong relationship between hepatic steatosis and elevated PPARγ expression, which suggest that PPARγ agonist administration could increase lipid accumulation in obese or hepatic PPARγ overexpressing mice [9, 11, 13, 17]. The gene discussed is PPARG; the disease is Hepatic steatosis.